It is unlike Baraclude generics will covet the Viread market
Launched with their low-price advantage, generic products of ‘Baraclude(generic name: entecavir),’ a chronic hepatitis B treatment, seem hard to impact on the market owned by ‘Viread(generic name: tenofovir).’
This is because the government has expressed its opinion that it is inappropriate to a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
